World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
104
Citations
62170
World Ranking
6903
National Ranking
198

Research.com Recognitions

  • 2019 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

Michael Friedlander is affiliated with the University of New South Wales in Australia and has a significant body of work in the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their research spans multiple subfields, including Oncology, Reproductive Medicine, Genetics, Pulmonary and Respiratory Medicine, and Cancer Research.

The scientist's main research topics cover ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, BRCA gene mutations in cancer, cancer treatment and pharmacology, endometrial and cervical cancer treatments, cancer genomics and diagnostics, and cancer survivorship and care.

Frequent co-authors collaborating with Michael Friedlander include:

  • Anna deFazio (28 collaborations)
  • Amit M. Oza (27 collaborations)
  • Penelope M. Webb (27 collaborations)
  • Chee Khoon Lee (25 collaborations)
  • Yeh Chen Lee (23 collaborations)

The publication venues where Michael Friedlander has regularly contributed are:

  • Gynecologic Oncology (30 publications)
  • Journal of Clinical Oncology (27 publications)
  • Annals of Oncology (14 publications)
  • International Journal of Gynecological Cancer (9 publications)
  • European Journal of Cancer (7 publications)

Some of their recent papers include:

  • Cancer of the ovary, fallopian tube, and peritoneum: 2021 update (2021) - International Journal of Gynecology & Obstetrics
  • Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial (2022) - Journal of Clinical Oncology
  • Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial (2021) - The Lancet Oncology
  • Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial (2020) - The Lancet Oncology
  • Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors (2020) - Journal for ImmunoTherapy of Cancer

Michael Friedlander has been recognized by being named a Fellow of the American Association for the Advancement of Science (AAAS) in 2019.

Best Publications

  • Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry

    D W Hedley;M L Friedlander;I W Taylor;C A Rugg

  • Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

    Karoline B. Kuchenbaecker;Karoline B. Kuchenbaecker;John L. Hopper;Daniel R. Barnes;Kelly-Anne Phillips

  • Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Kathleen Moore;Nicoletta Colombo;Giovanni Scambia;Byoung Gie Kim

  • Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

    Andrew Tutt;Mark Robson;Judy E Garber;Susan M Domchek

  • Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer

    A Tutt;M Robson;J E Garber;S M Domchek

  • Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

    Jonathan Ledermann;Philipp Harter;Charlie Gourley;Michael Friedlander

  • Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

    Eric Pujade-Lauraine;Jonathan A Ledermann;Frédéric Selle;Val Gebski

  • Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation

    Bella Kaufman;Ronnie Shapira-Frommer;Rita K. Schmutzler;M. William Audeh

  • Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

    Jonathan Ledermann;Philipp Harter;Charlie Gourley;Michael Friedlander

  • Rethinking ovarian cancer: recommendations for improving outcomes

    Sebastian Vaughan;Jermaine I. Coward;Robert C. Bast;Andy Berchuck

  • Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

    Robert L Coleman;Amit M Oza;Domenica Lorusso;Carol Aghajanian

  • Whole-genome characterization of chemoresistant ovarian cancer

    Ann-Marie Patch;Ann-Marie Patch;Elizabeth Christie;Dariush Etemadmoghadam;Dariush Etemadmoghadam;Dale W. Garsed

  • BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group

    Kathryn Alsop;Sian Fereday;Cliff Meldrum;Anna deFazio

  • Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup

    Michael A. Bookman;Mark F. Brady;William P. McGuire;Peter G. Harper

  • Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

    Robert L. Coleman;Gini F. Fleming;Mark F. Brady;Elizabeth M. Swisher

  • Chemotherapy-induced peripheral neurotoxicity: a critical analysis.

    Susanna B. Park;David Goldstein;Arun V. Krishnan;Cindy S-Y Lin

  • Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).

    Gordon John Sampson Rustin;Ignace Vergote;Elizabeth Eisenhauer;Eric Pujade-Lauraine

  • Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer

    Stan B. Kaye;Jan Lubinski;Ursula Matulonis;Joo Ern Ang

  • Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial

    Amit M Oza;David Cibula;Ana Oaknin Benzaquen;Christopher Poole

  • Clinical and biological significance of aneuploidy in human tumours.

    M L Friedlander;D W Hedley;I W Taylor

Frequent Co-Authors

David Goldstein
David Goldstein University of New South Wales
Amit M. Oza
Amit M. Oza Princess Margaret Cancer Centre
Roger L. Milne
Roger L. Milne Cancer Council Victoria
Val Gebski
Val Gebski University of Sydney
John L. Hopper
John L. Hopper University of Melbourne
Clare L. Scott
Clare L. Scott Walter and Eliza Hall Institute of Medical Research
Nicoletta Colombo
Nicoletta Colombo University of Milano-Bicocca
Madeleine King
Madeleine King University of Sydney
David D.L. Bowtell
David D.L. Bowtell Peter MacCallum Cancer Centre
Irene L. Andrulis
Irene L. Andrulis University of Toronto

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a career in Medicine or a related healthcare field, exploring online degrees can open many doors. Today, healthcare professionals have more flexible study options than ever before, allowing you to balance work, personal commitments, and education.

For advanced nursing roles, those looking for cheap dnp online programs can find affordable online routes to earn a Doctor of Nursing Practice, ideal for leadership and advanced clinical positions.

Similarly, pharmacists can study remotely. If you’re interested in becoming a licensed pharmacist, consider exploring your options for an online pharmacist degree to gain the credentials needed for this high-demand role.

Not all medical careers require direct patient care. Those drawn to healthcare administration could benefit from a health information management degree online, focusing on the organization and security of medical data.

Lastly, an entry-level option such as the cheapest medical coding certification online can provide a fast track to working in medical billing and coding with flexible study and affordable tuition.

Best Scientists Citing Michael Friedlander

Trending Scientists

Recently Published Articles